Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 5/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 5/20 | 0.33 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.32 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.32 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.32 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.32 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948204 | 0.78 | HSPA5 (0.42) | HSPA5 | |
| SCHEMBL8764257 | 0.78 | HSPA5 (0.42) | HSPA5 | |
| SCHEMBL1509747 | 0.77 | HSPA5 (0.50) | HSPA5NPC1RAB9A | |
| SCHEMBL27558441 | 0.77 | HSPA5 (0.50) | HSPA5NPC1RAB9A | |
| SCHEMBL12724861 | 0.75 | HSPA5 (0.53) | HSPA5NPC1RAB9AFPR2SMN1; SMN2 | |
| SCHEMBL12450659 | 0.75 | KDM4E (0.44) | HDAC1 | |
| SCHEMBL8890772 | 0.73 | HSPA5 (0.49) | HSPA5NPC1RAB9AMMP1MMP3 | |
| SCHEMBL8890777 | 0.73 | HSPA5 (0.49) | HSPA5NPC1RAB9AMMP1MMP3 | |
| SCHEMBL11252147 | 0.71 | PRMT5 (0.47) | HSPA5NPC1RAB9APRMT5WDR77 | |
| SCHEMBL12450681 | 0.71 | MMP2 (0.39) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | HSPA5 1786/4885NPC1 655/4885RAB9A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.